Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis

Phase II Study Intravitreally Admininstered Ranibizumab in 50 Subjects With AMD Having Received at Least 3 Doses of Intermittent Anti-VEGF Therapy in the Preceding 18 Months

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00804934

Enrollment

100

Registered

2008-12-09

Start date

2008-02-29

Completion date

2009-01-31

Last updated

2012-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wet AMD

Brief summary

The purpose of this study is to determine whether people who have received intermittent anti-VEGF therapy have an improvement in vision after being switched to monthly injections of Lucentis.

Detailed description

To determine mean change in visual acuity at 6 and 12 months

Interventions

DRUGLucentis

0.5mg Lucentis every four months

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* Ability to provide written informed consent and comply with study assessments for the full duration of the study * Age greater then and equal 50 years * Patients with active neovascular AMD * Received at least 3 treatments with anti-VEGF therapy (bevacizumab or pegaptanib or ranibizumab) in the last 24 months * If the patient has bilateral disease and qualifies for the study, both eyes may be included

Exclusion criteria

* Subjects who meet any of the following criteria will be excluded from this study: * Pregnancy or lactation * Premenopausal women not using adequate contraception. * Participation in another simultaneous medical investigation

Design outcomes

Primary

Measure	Time frame
Mean change in visual acuity at 6 and 12 months	one year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026